A randomized, four-way crossover, comparative bio-availability study of branded (Neurontin) and three generic 800 mg gabapentin tablets in healthy subjects under fasting conditions

Trial Profile

A randomized, four-way crossover, comparative bio-availability study of branded (Neurontin) and three generic 800 mg gabapentin tablets in healthy subjects under fasting conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Gabapentin (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2013 Results presented at the 11th Congress of the European Association for Clinical Pharmacology and Therapeutics.
    • 31 Aug 2013 Primary endpoint 'Peak-drug-concentration' has been met.
    • 31 Aug 2013 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top